APA (7th ed.) Citation

Jimeno, A., Shirai, K., Choi, M., Laskin, J., Kochenderfer, M., Spira, A., . . . Cohen, R. B. (2015). A randomized, phase II trial of cetuximab with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer. Annals of Oncology, 26(3), 556. https://doi.org/10.1093/annonc/mdu574

Chicago Style (17th ed.) Citation

Jimeno, A., et al. "A Randomized, Phase II Trial of Cetuximab with or Without PX-866, an Irreversible Oral Phosphatidylinositol 3-kinase Inhibitor, in Patients with Relapsed or Metastatic Head and Neck Squamous Cell Cancer." Annals of Oncology 26, no. 3 (2015): 556. https://doi.org/10.1093/annonc/mdu574.

MLA (9th ed.) Citation

Jimeno, A., et al. "A Randomized, Phase II Trial of Cetuximab with or Without PX-866, an Irreversible Oral Phosphatidylinositol 3-kinase Inhibitor, in Patients with Relapsed or Metastatic Head and Neck Squamous Cell Cancer." Annals of Oncology, vol. 26, no. 3, 2015, p. 556, https://doi.org/10.1093/annonc/mdu574.